- Home
- Publications
- Publication Search
- Publication Details
Title
Role of EGFR and FASN in breast cancer progression
Authors
Keywords
-
Journal
Journal of Cell Communication and Signaling
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-07-25
DOI
10.1007/s12079-023-00771-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
- (2022) Albert K. Kwan et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Fatty acid synthetase expression in triple-negative breast cancer
- (2022) Jin Hee Park et al. Journal of Pathology and Translational Medicine
- “The emerging role of capivasertib in breast cancer”
- (2022) Angeliki Andrikopoulou et al. BREAST
- Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686
- (2022) Qinlan Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
- (2022) Po-Han Lin et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling
- (2022) Min Zhou et al. MOLECULAR THERAPY
- Lobular Breast Cancer: A Review
- (2021) Natalie Wilson et al. Frontiers in Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems
- (2021) Xiaojuan Qu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives
- (2021) Dwan-Ying Chang et al. Therapeutics and Clinical Risk Management
- Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
- (2021) Javier A. Menendez et al. Cancers
- FASN inhibition as a potential treatment for endocrine-resistant breast cancer
- (2021) Aleksandra Gruslova et al. BREAST CANCER RESEARCH AND TREATMENT
- Current State of Breast Cancer Diagnosis, Treatment, and Theranostics
- (2021) Arya Bhushan et al. Pharmaceutics
- Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC
- (2021) Sagar D. Sardesai et al. CLINICAL CANCER RESEARCH
- Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.
- (2021) Justin Wayne Wong Tiu-lim et al. JOURNAL OF CLINICAL ONCOLOGY
- MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study
- (2021) Weihua Jiang et al. Frontiers in Oncology
- FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
- (2021) Erica C. Nakajima et al. CLINICAL CANCER RESEARCH
- FASN-Dependent Lipid Metabolism Links Neurogenic Stem/Progenitor Cell Activity to Learning and Memory Deficits
- (2020) Megan Bowers et al. Cell Stem Cell
- FABP4: A New Player in Obesity-Associated Breast Cancer
- (2020) Jun Zeng et al. TRENDS IN MOLECULAR MEDICINE
- SUMOylation Protects FASN Against Proteasomal Degradation in Breast Cancer Cells Treated with Grape Leaf Extract
- (2020) Andrea Floris et al. Biomolecules
- A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
- (2020) Adileh Ayati et al. BIOORGANIC CHEMISTRY
- Histology of Luminal Breast Cancer
- (2020) Ramona Erber et al. Breast Care
- Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib
- (2020) Yujie Liu et al. LUNG CANCER
- SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR
- (2020) Lina Zhao et al. Advanced Science
- The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
- (2020) Wen-Qi Cai et al. Frontiers in Oncology
- Fatty Acid Synthase: An Emerging Target in Cancer
- (2020) Chee Wai Fhu et al. MOLECULES
- Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis
- (2020) Ying Chen et al. Frontiers in Cell and Developmental Biology
- Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis
- (2020) Junmei Yi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells
- (2020) Peter Cruz-Gordillo et al. Science Signaling
- Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs
- (2020) Yun Chen et al. ACS Medicinal Chemistry Letters
- First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
- (2019) Masayuki Takeda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Recognizing and appraising symptoms of breast cancer as a reason for delayed presentation in Ghanaian women: A qualitative study
- (2019) Adwoa Bemah Bonsu et al. PLoS One
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models
- (2019) Ariadna Giró-Perafita et al. MOLECULES
- Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
- (2019) Mohamed-Reda Benmebarek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
- (2019) Ayesha Murtuza et al. CANCER RESEARCH
- Class II PI3K Functions in Cell Biology and Disease
- (2019) Federico Gulluni et al. TRENDS IN CELL BIOLOGY
- FEN1 mediates miR-200a methylation and promotes breast cancer cell growth via MET and EGFR signaling
- (2019) Xue Zeng et al. FASEB JOURNAL
- Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer
- (2019) Kathleen Fenn et al. Clinical Breast Cancer
- In vitro elimination of EGFR‐overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab
- (2019) Sara Caratelli et al. INTERNATIONAL JOURNAL OF CANCER
- STAT3 and STAT5 Activation in Solid Cancers
- (2019) Sebastian Igelmann et al. Cancers
- Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
- (2019) Nedeljković et al. Cells
- Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
- (2019) Rachel Grosser et al. CANCER CELL
- HUNK phosphorylates EGFR to regulate breast cancer metastasis
- (2019) Carly B. Williams et al. ONCOGENE
- RAS as Supporting Actor in Breast Cancer
- (2019) Mirco Galiè Frontiers in Oncology
- EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
- (2019) Yan Liu et al. Aging-US
- KRAS4A directly regulates hexokinase 1
- (2019) Caroline R. Amendola et al. NATURE
- Inhibition of FASN and ERα signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism
- (2018) H.A. Zielinska et al. CANCER LETTERS
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways
- (2018) Yuanyuan Zhao et al. Molecular Oncology
- Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL
- (2018) Bandish Kapadia et al. Nature Communications
- Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer
- (2018) Yekaterina Y. Zaytseva et al. Oncotarget
- Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells
- (2018) Jones Gyamfi et al. Scientific Reports
- Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
- (2018) Naoko Matsuda et al. JAMA Oncology
- Circulating Adipose Fatty Acid Binding Protein Is a New Link Underlying Obesity-Associated Breast/Mammary Tumor Development
- (2018) Jiaqing Hao et al. Cell Metabolism
- The Akt pathway in oncology therapy and beyond (Review)
- (2018) George Nitulescu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
- (2017) Mathilde Guerin et al. EUROPEAN JOURNAL OF CANCER
- Fatty acid synthase (FASN) as a therapeutic target in breast cancer
- (2017) Javier A. Menendez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Risk Factors and Preventions of Breast Cancer
- (2017) Yi-Sheng Sun et al. International Journal of Biological Sciences
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis
- (2017) Linshan Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
- (2017) Sarah J. Ross et al. Science Translational Medicine
- Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
- (2017) Ariadna Giró-Perafita et al. Oncotarget
- The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
- (2017) Wen-Zhao Zhong et al. Oncotarget
- Trastuzumab in the Treatment of Breast Cancer
- (2016) Sofia Maximiano et al. BIODRUGS
- MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer
- (2016) Zhengzhi Zhu et al. BIOLOGICAL CHEMISTRY
- Recent progress on third generation covalent EGFR inhibitors
- (2016) Hengmiao Cheng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling
- (2016) Whitney S. Henry et al. CANCER RESEARCH
- Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
- (2016) A. Giro-Perafita et al. CLINICAL CANCER RESEARCH
- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Necitumumab: First Global Approval
- (2016) Karly P. Garnock-Jones DRUGS
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration
- (2016) LAN ZHOU et al. ONCOLOGY REPORTS
- Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer
- (2016) Jingxuan Wang et al. Oncotarget
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer
- (2015) Yong Bian et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer
- (2015) Kenneth K W To et al. BRITISH JOURNAL OF PHARMACOLOGY
- Understanding rural–urban differences in risk factors for breast cancer in an Indian population
- (2015) Rajini Nagrani et al. CANCER CAUSES & CONTROL
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
- (2015) Olivier Trédan et al. Clinical Breast Cancer
- Molecular Pathways: Fatty Acid Synthase
- (2015) S. F. Jones et al. CLINICAL CANCER RESEARCH
- The Arf and Rab11 effector FIP3 acts synergistically with ASAP1 to direct Rabin8 in ciliary receptor targeting
- (2015) J. Wang et al. JOURNAL OF CELL SCIENCE
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP
- (2015) S J H Ricoult et al. ONCOGENE
- Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
- (2015) Lakshmi Reddy Bollu et al. Oncotarget
- Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation
- (2015) Ze-Yi Zheng et al. Cell Reports
- Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells
- (2015) Graziela Rosa Ravacci et al. Biomed Research International
- Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression
- (2015) Richard Ventura et al. EBioMedicine
- The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer
- (2015) Vahid Bemanian et al. PLoS One
- The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer
- (2015) Martin C. Sadowski et al. Oncotarget
- Fatty acid synthase is required for mammary gland development and milk production during lactation
- (2014) Janel Suburu et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Predictive Factors and Patterns of Recurrence in Patients with Triple Negative Breast Cancer
- (2014) Lauren Steward et al. ANNALS OF SURGICAL ONCOLOGY
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer
- (2014) Sara Tolaney et al. BREAST CANCER RESEARCH AND TREATMENT
- Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
- (2014) V Secq et al. BRITISH JOURNAL OF CANCER
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Abstract 1891: Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119.
- (2014) Erin Brophy et al. CANCER RESEARCH
- Breast Cancer: Epidemiology and Etiology
- (2014) ZiQi Tao et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine
- (2014) Chien-shan Cheng et al. Evidence-based Complementary and Alternative Medicine
- Classes of phosphoinositide 3-kinases at a glance
- (2014) S. Jean et al. JOURNAL OF CELL SCIENCE
- A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site
- (2014) Mary Ann Hardwicke et al. Nature Chemical Biology
- Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase
- (2014) Valerie E. Fako et al. ACS Catalysis
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells
- (2014) Kumiko Oida et al. Scientific Reports
- St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
- (2013) Nadia Harbeck et al. Breast Care
- Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer
- (2013) K. M. J. De Bruijn et al. BRITISH JOURNAL OF SURGERY
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
- (2013) Rachel M. Layman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cell survival and metastasis regulation by Akt signaling in colorectal cancer
- (2013) Ekta Agarwal et al. CELLULAR SIGNALLING
- Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells
- (2013) RISA SHIRAGAMI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade
- (2013) Bang-Bao Tao et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer
- (2013) Zhongzhen Guan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Afatinib—new therapy option for EGFR-mutant lung cancer
- (2013) Helena A. Yu et al. Nature Reviews Clinical Oncology
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nimotuzumab treatment of malignant gliomas
- (2012) Udo Bode et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Fatty Acid Synthase Inhibition by Amentoflavone Suppresses HER2/neu(erbB2) Oncogene in SKBR3 Human Breast Cancer Cells
- (2012) Jin Sun Lee et al. PHYTOTHERAPY RESEARCH
- Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer
- (2012) Hiroki Nakajima et al. Breast Cancer
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Incidence and Outcome of Male Breast Cancer: An International Population-Based Study
- (2011) Hui Miao et al. JOURNAL OF CLINICAL ONCOLOGY
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
- (2010) G. Zoppoli et al. CURRENT CANCER DRUG TARGETS
- STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer
- (2010) Dimitrios Iliopoulos et al. MOLECULAR CELL
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer
- (2009) H. Zhang et al. BREAST CANCER RESEARCH AND TREATMENT
- De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
- (2009) T Mashima et al. BRITISH JOURNAL OF CANCER
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
- (2008) Maura N. Dickler et al. BREAST CANCER RESEARCH AND TREATMENT
- Fatty Acid Synthase Gene Is Up-regulated by Hypoxia via Activation of Akt and Sterol Regulatory Element Binding Protein-1
- (2008) E. Furuta et al. CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma
- (2008) J. Bean et al. CLINICAL CANCER RESEARCH
- Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction
- (2008) María Jesús Vázquez et al. FEBS Journal
- Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model
- (2008) Marco A. Carvalho et al. INTERNATIONAL JOURNAL OF CANCER
- A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction
- (2008) H. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
- (2008) Masato Furuhashi et al. NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started